Logo image of INMD

INMODE LTD (INMD) Stock Fundamental Analysis

NASDAQ:INMD - Nasdaq - IL0011595993 - Common Stock - Currency: USD

14.19  -0.1 (-0.7%)

Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to INMD. INMD was compared to 188 industry peers in the Health Care Equipment & Supplies industry. INMD gets an excellent profitability rating and is at the same time showing great financial health properties. INMD may be a bit undervalued, certainly considering the very reasonable score on growth This makes INMD very considerable for value investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

INMD had positive earnings in the past year.
In the past year INMD had a positive cash flow from operations.
In the past 5 years INMD has always been profitable.
In the past 5 years INMD always reported a positive cash flow from operatings.
INMD Yearly Net Income VS EBIT VS OCF VS FCFINMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

1.2 Ratios

INMD's Return On Assets of 24.94% is amongst the best of the industry. INMD outperforms 98.40% of its industry peers.
INMD has a Return On Equity of 28.38%. This is amongst the best in the industry. INMD outperforms 97.34% of its industry peers.
Looking at the Return On Invested Capital, with a value of 15.86%, INMD belongs to the top of the industry, outperforming 96.81% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for INMD is significantly above the industry average of 7.89%.
The 3 year average ROIC (22.89%) for INMD is well above the current ROIC(15.86%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 24.94%
ROE 28.38%
ROIC 15.86%
ROA(3y)23.69%
ROA(5y)26.18%
ROE(3y)26.67%
ROE(5y)29.84%
ROIC(3y)22.89%
ROIC(5y)25.97%
INMD Yearly ROA, ROE, ROICINMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

1.3 Margins

With an excellent Profit Margin value of 44.80%, INMD belongs to the best of the industry, outperforming 98.40% of the companies in the same industry.
INMD's Profit Margin has improved in the last couple of years.
INMD's Operating Margin of 28.05% is amongst the best of the industry. INMD outperforms 96.81% of its industry peers.
In the last couple of years the Operating Margin of INMD has declined.
INMD has a Gross Margin of 80.03%. This is amongst the best in the industry. INMD outperforms 93.62% of its industry peers.
INMD's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 28.05%
PM (TTM) 44.8%
GM 80.03%
OM growth 3Y-15.26%
OM growth 5Y-5.64%
PM growth 3Y-0.16%
PM growth 5Y3.28%
GM growth 3Y-1.88%
GM growth 5Y-1.59%
INMD Yearly Profit, Operating, Gross MarginsINMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so INMD is creating value.
The number of shares outstanding for INMD has been reduced compared to 1 year ago.
INMD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for INMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INMD Yearly Shares OutstandingINMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
INMD Yearly Total Debt VS Total AssetsINMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

There is no outstanding debt for INMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.76
WACC9.02%
INMD Yearly LT Debt VS Equity VS FCFINMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.3 Liquidity

INMD has a Current Ratio of 8.73. This indicates that INMD is financially healthy and has no problem in meeting its short term obligations.
INMD has a better Current ratio (8.73) than 89.89% of its industry peers.
A Quick Ratio of 7.86 indicates that INMD has no problem at all paying its short term obligations.
The Quick ratio of INMD (7.86) is better than 91.49% of its industry peers.
Industry RankSector Rank
Current Ratio 8.73
Quick Ratio 7.86
INMD Yearly Current Assets VS Current LiabilitesINMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

4

3. Growth

3.1 Past

INMD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.00%.
The Earnings Per Share has been growing by 22.97% on average over the past years. This is a very strong growth
The Revenue for INMD has decreased by -15.84% in the past year. This is quite bad
Measured over the past years, INMD shows a very strong growth in Revenue. The Revenue has been growing by 20.35% on average per year.
EPS 1Y (TTM)-25%
EPS 3Y-4.52%
EPS 5Y22.97%
EPS Q2Q%-3.13%
Revenue 1Y (TTM)-15.84%
Revenue growth 3Y3.36%
Revenue growth 5Y20.35%
Sales Q2Q%-3%

3.2 Future

INMD is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.02% yearly.
INMD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.35% yearly.
EPS Next Y-3.04%
EPS Next 2Y3.74%
EPS Next 3Y5.02%
EPS Next 5YN/A
Revenue Next Year-4.01%
Revenue Next 2Y0.8%
Revenue Next 3Y3.35%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
INMD Yearly Revenue VS EstimatesINMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
INMD Yearly EPS VS EstimatesINMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2 2.5

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

INMD is valuated reasonably with a Price/Earnings ratio of 8.02.
INMD's Price/Earnings ratio is rather cheap when compared to the industry. INMD is cheaper than 96.28% of the companies in the same industry.
INMD's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.55.
INMD is valuated cheaply with a Price/Forward Earnings ratio of 7.41.
Based on the Price/Forward Earnings ratio, INMD is valued cheaply inside the industry as 96.81% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 22.40. INMD is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 8.02
Fwd PE 7.41
INMD Price Earnings VS Forward Price EarningsINMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

99.47% of the companies in the same industry are more expensive than INMD, based on the Enterprise Value to EBITDA ratio.
INMD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. INMD is cheaper than 97.87% of the companies in the same industry.
Industry RankSector Rank
P/FCF 7.35
EV/EBITDA 1.49
INMD Per share dataINMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

INMD has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.35
EPS Next 2Y3.74%
EPS Next 3Y5.02%

More info and screens

0

5. Dividend

5.1 Amount

INMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INMODE LTD

NASDAQ:INMD (6/12/2025, 11:03:58 AM)

14.19

-0.1 (-0.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-28 2025-04-28/bmo
Earnings (Next)07-30 2025-07-30/bmo
Inst Owners65.62%
Inst Owner Change1.86%
Ins Owners9.67%
Ins Owner ChangeN/A
Market Cap896.95M
Analysts75.38
Price Target17.6 (24.03%)
Short Float %10.89%
Short Ratio3.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.98%
Min EPS beat(2)-20.27%
Max EPS beat(2)-13.69%
EPS beat(4)1
Avg EPS beat(4)-9.56%
Min EPS beat(4)-20.27%
Max EPS beat(4)8.88%
EPS beat(8)3
Avg EPS beat(8)-6.75%
EPS beat(12)7
Avg EPS beat(12)-0.58%
EPS beat(16)11
Avg EPS beat(16)2.13%
Revenue beat(2)0
Avg Revenue beat(2)-6.17%
Min Revenue beat(2)-9.96%
Max Revenue beat(2)-2.38%
Revenue beat(4)1
Avg Revenue beat(4)-7.11%
Min Revenue beat(4)-16.64%
Max Revenue beat(4)0.53%
Revenue beat(8)2
Avg Revenue beat(8)-6.51%
Revenue beat(12)6
Avg Revenue beat(12)-2.94%
Revenue beat(16)10
Avg Revenue beat(16)-0.79%
PT rev (1m)-6.97%
PT rev (3m)-19.14%
EPS NQ rev (1m)-2.36%
EPS NQ rev (3m)-14.53%
EPS NY rev (1m)-12.17%
EPS NY rev (3m)-12.81%
Revenue NQ rev (1m)0.11%
Revenue NQ rev (3m)-0.31%
Revenue NY rev (1m)-0.14%
Revenue NY rev (3m)-1.63%
Valuation
Industry RankSector Rank
PE 8.02
Fwd PE 7.41
P/S 2.29
P/FCF 7.35
P/OCF 7.32
P/B 1.45
P/tB 1.45
EV/EBITDA 1.49
EPS(TTM)1.77
EY12.47%
EPS(NY)1.92
Fwd EY13.5%
FCF(TTM)1.93
FCFY13.6%
OCF(TTM)1.94
OCFY13.67%
SpS6.21
BVpS9.8
TBVpS9.8
PEG (NY)N/A
PEG (5Y)0.35
Profitability
Industry RankSector Rank
ROA 24.94%
ROE 28.38%
ROCE 17.41%
ROIC 15.86%
ROICexc 84.14%
ROICexgc 84.14%
OM 28.05%
PM (TTM) 44.8%
GM 80.03%
FCFM 31.08%
ROA(3y)23.69%
ROA(5y)26.18%
ROE(3y)26.67%
ROE(5y)29.84%
ROIC(3y)22.89%
ROIC(5y)25.97%
ROICexc(3y)532.49%
ROICexc(5y)5023.19%
ROICexgc(3y)532.49%
ROICexgc(5y)5023.19%
ROCE(3y)25.13%
ROCE(5y)28.51%
ROICexcg growth 3Y-60.68%
ROICexcg growth 5YN/A
ROICexc growth 3Y-60.68%
ROICexc growth 5YN/A
OM growth 3Y-15.26%
OM growth 5Y-5.64%
PM growth 3Y-0.16%
PM growth 5Y3.28%
GM growth 3Y-1.88%
GM growth 5Y-1.59%
F-Score6
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 87.11%
Cap/Sales 0.16%
Interest Coverage 250
Cash Conversion 110.65%
Profit Quality 69.38%
Current Ratio 8.73
Quick Ratio 7.86
Altman-Z N/A
F-Score6
WACC9.02%
ROIC/WACC1.76
Cap/Depr(3y)144.54%
Cap/Depr(5y)147.73%
Cap/Sales(3y)0.22%
Cap/Sales(5y)0.23%
Profit Quality(3y)91.09%
Profit Quality(5y)96.73%
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3Y-4.52%
EPS 5Y22.97%
EPS Q2Q%-3.13%
EPS Next Y-3.04%
EPS Next 2Y3.74%
EPS Next 3Y5.02%
EPS Next 5YN/A
Revenue 1Y (TTM)-15.84%
Revenue growth 3Y3.36%
Revenue growth 5Y20.35%
Sales Q2Q%-3%
Revenue Next Year-4.01%
Revenue Next 2Y0.8%
Revenue Next 3Y3.35%
Revenue Next 5YN/A
EBIT growth 1Y-36.29%
EBIT growth 3Y-12.42%
EBIT growth 5Y13.55%
EBIT Next Year-31.82%
EBIT Next 3Y-5%
EBIT Next 5YN/A
FCF growth 1Y-27.92%
FCF growth 3Y-8.8%
FCF growth 5Y16.5%
OCF growth 1Y-28.22%
OCF growth 3Y-8.8%
OCF growth 5Y16.36%